Eupraxia Pharmaceuticals announced its management team will present and participate in two upcoming investor conferences in April 2026.
Key takeaways
Management will participate in 1x1 meetings at the Raymond James Biotech Innovation Symposium in New York on April 14, 2026.
The company will present and hold 1x1 meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026.
The Bloom Burton presentation on April 21 at 11:00 AM ET will be webcast via a provided link.
The company is a clinical-stage biotechnology company focused on locally delivered, extended-release products using its Diffusphere™ technology.
Eupraxia's pipeline includes EP-104GI in a Phase 1b/2 trial for EoE and EP-104IAR, which met its primary endpoint in a Phase 2b trial for knee osteoarthritis pain.